

Ezekiel J Emanuel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7083506/publications.pdf>

Version: 2024-02-01

142
papers

9,763
citations

101543
36
h-index

40979
93
g-index

145
all docs

145
docs citations

145
times ranked

16621
citing authors

#	ARTICLE	IF	CITATIONS
1	A National Strategy for COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 213.	7.4	11
2	A National Strategy for COVID-19 Medical Countermeasures. JAMA - Journal of the American Medical Association, 2022, 327, 215.	7.4	19
3	A National Strategy for the “New Normal” of Life With COVID. JAMA - Journal of the American Medical Association, 2022, 327, 211.	7.4	59
4	Accurate long-term prediction of death for patients with cirrhosis. Hepatology, 2022, 76, 700-711.	7.3	5
5	Aligning Incentives for Improving Diagnostic Excellence. JAMA - Journal of the American Medical Association, 2022, 327, 1543.	7.4	3
6	Strategy for the “New Normal” of Life With COVID—Reply. JAMA - Journal of the American Medical Association, 2022, 327, 1824.	7.4	2
7	Testing, Surveillance, and Mitigation Strategies for COVID-19—Reply. JAMA - Journal of the American Medical Association, 2022, 327, 1825.	7.4	0
8	Incentives for Palliative Care. Journal of Palliative Medicine, 2022, 25, 1024-1030.	1.1	3
9	Designing a commercial bundle for cardiac procedures: The Percutaneous Coronary Intervention Episode Payment Model. Healthcare, 2021, 9, 100426.	1.3	2
10	Covax must go beyond proportional allocation of covid vaccines to ensure fair and equitable access. BMJ, The, 2021, 372, m4853.	6.0	70
11	Comparing Health Outcomes of Privileged US Citizens With Those of Average Residents of Other Developed Countries. JAMA Internal Medicine, 2021, 181, 339.	5.1	27
12	Better Late Than Never: Trends in COVID-19 Infection Rates, Risk Perceptions, and Behavioral Responses in the USA. Journal of General Internal Medicine, 2021, 36, 1825-1828.	2.6	12
13	Enhancing the WHO’s Proposed Framework for Distributing COVID-19 Vaccines Among Countries. American Journal of Public Health, 2021, 111, 371-373.	2.7	23
14	Assessment of Length and Readability of Informed Consent Documents for COVID-19 Vaccine Trials. JAMA Network Open, 2021, 4, e2110843.	5.9	29
15	Public Perspectives on COVID-19 Vaccine Prioritization. JAMA Network Open, 2021, 4, e217943.	5.9	45
16	The Near-Term Future of Health Care Reform. JAMA - Journal of the American Medical Association, 2021, 325, 1394.	7.4	3
17	Ethical and policy considerations for COVID-19 vaccination modalities: delayed second dose, fractional dose, mixed vaccines. BMJ Global Health, 2021, 6, e005912.	4.7	6
18	Designing a Successful Primary Care Physician Capitation Model. JAMA - Journal of the American Medical Association, 2021, 325, 2043.	7.4	7

#	ARTICLE	IF	CITATIONS
19	Development and Validation of a Model to Predict Long-Term Survival After Liver Transplantation. Liver Transplantation, 2021, 27, 797-807.	2.4	10
20	Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score. Journal of Hepatology, 2021, 74, 1398-1406.	3.7	23
21	Ethical Considerations of Offering Benefits to COVID-19 Vaccine Recipients. JAMA - Journal of the American Medical Association, 2021, 326, 221.	7.4	24
22	What are the obligations of pharmaceutical companies in a global health emergency?. Lancet, The, 2021, 398, 1015-1020.	13.7	22
23	Vaccine nationalism and the dynamics and control of SARS-CoV-2. Science, 2021, 373, eabj7364.	12.6	80
24	Making Vaccines Available to Other Countries Before Offering Domestic Booster Vaccinations. JAMA - Journal of the American Medical Association, 2021, 326, 903.	7.4	29
25	A Middle Ground for Accelerated Drug Approval—Lessons From Aducanumab. JAMA - Journal of the American Medical Association, 2021, 326, 1367-1368.	7.4	10
26	Immunity certification for COVID-19: ethical considerations. Bulletin of the World Health Organization, 2021, 99, 155-161.	3.3	43
27	Paying for Cancer Drugs That Prove Their Benefit. JAMA - Journal of the American Medical Association, 2021, 326, 1579.	7.4	4
28	On the Ethics of Vaccine Nationalism: The Case for the Fair Priority for Residents Framework. Ethics and International Affairs, 2021, 35, 543-562.	0.3	16
29	Obligations in a global health emergency — Authors' reply. Lancet, The, 2021, 398, 2072.	13.7	2
30	Considering the Future of Price Transparency Initiatives—Information Alone Is Not Sufficient. JAMA Network Open, 2021, 4, e2137566.	5.9	4
31	Changes in Outpatient Imaging Utilization and Spending Under a New Population-Based Primary Care Payment Model. Journal of the American College of Radiology, 2020, 17, 101-109.	1.8	3
32	Spending And Quality After Three Years Of Medicare's Voluntary Bundled Payment For Joint Replacement Surgery. Health Affairs, 2020, 39, 58-66.	5.2	48
33	Reconfiguring Medical Education—Reply. JAMA - Journal of the American Medical Association, 2020, 324, 1007.	7.4	0
34	COVID-19 and Excess All-Cause Mortality in the US and 18 Comparison Countries. JAMA - Journal of the American Medical Association, 2020, 324, 2100.	7.4	188
35	Drug Reimbursement Regulation in 6 Peer Countries. JAMA Internal Medicine, 2020, 180, 1510.	5.1	29
36	Alternative Payment Models—Victims of Their Own Success?. JAMA - Journal of the American Medical Association, 2020, 324, 237.	7.4	12

#	ARTICLE	IF	CITATIONS
37	Should Pediatric Patients Be Prioritized When Rationing Life-Saving Treatments During COVID-19 Pandemic. Pediatrics, 2020, 146, .	2.1	10
38	Key Ethical Concepts and Their Application to COVID-19 Research. Public Health Ethics, 2020, 13, 127-132.	1.0	25
39	Hospice Carve-In”Aligning Benefits With Patient and Family Needs. JAMA - Journal of the American Medical Association, 2020, 324, 35.	7.4	5
40	Outpatient Treatment at Home for Medicare Beneficiaries During and After the COVID-19 Pandemic. JAMA - Journal of the American Medical Association, 2020, 324, 21.	7.4	7
41	Spillover effects of mandatory hip and knee replacement surgery bundles in medicare. Healthcare, 2020, 8, 100447.	1.3	3
42	An ethical framework for global vaccine allocation. Science, 2020, 369, 1309-1312.	12.6	235
43	Fairly Prioritizing Groups for Access to COVID-19 Vaccines. JAMA - Journal of the American Medical Association, 2020, 324, 1601.	7.4	183
44	The Ethics of COVID-19 Immunity-Based Licenses (”Immunity Passports”). JAMA - Journal of the American Medical Association, 2020, 323, 2241.	7.4	82
45	Assessing The Effectiveness Of Peer Comparisons As A Way To Improve Health Care Quality. Health Affairs, 2020, 39, 852-861.	5.2	19
46	Publication Ethics During Public Health Emergencies Such as the COVID-19 Pandemic. American Journal of Public Health, 2020, 110, 947-948.	2.7	21
47	Fair Allocation of Scarce Medical Resources in the Time of Covid-19. New England Journal of Medicine, 2020, 382, 2049-2055.	27.0	2,322
48	Spending and quality after three years of Medicare’s bundled payments for medical conditions: quasi-experimental difference-in-differences study. BMJ, The, 2020, 369, m1780.	6.0	29
49	The Inevitable Reimagining of Medical Education. JAMA - Journal of the American Medical Association, 2020, 323, 1127.	7.4	201
50	Sharing Patient Data Without Exploiting Patients. JAMA - Journal of the American Medical Association, 2020, 323, 505.	7.4	22
51	Association of Social Mobility With the Income-Related Longevity Gap in the United States. JAMA Internal Medicine, 2020, 180, 429.	5.1	20
52	Designing a commercial medical bundle for cancer care: Hawaii Medical Service Association's Cancer Episode Model. Healthcare, 2020, 8, 100422.	1.3	2
53	US Public Attitudes Toward COVID-19 Vaccine Mandates. JAMA Network Open, 2020, 3, e2033324.	5.9	98
54	Assessing Alternative Payment Models”Reply. JAMA - Journal of the American Medical Association, 2020, 324, 1998.	7.4	0

#	ARTICLE	IF	CITATIONS
55	Outcomes Associated With Overlapping Surgery. JAMA - Journal of the American Medical Association, 2019, 322, 274.	7.4	0
56	Accuracy Of The Relative Value Scale Update Committee's Time Estimates And Physician Fee Schedule For Joint Replacement. Health Affairs, 2019, 38, 1079-1086.	5.2	25
57	Association Between the Implementation of a Population-Based Primary Care Payment System and Achievement on Quality Measures in Hawaii. JAMA - Journal of the American Medical Association, 2019, 322, 57.	7.4	24
58	Reply to "Separating neuroethics from neurohype". Nature Biotechnology, 2019, 37, 991-992.	17.5	1
59	The Relative Value Scale Update Committee. JAMA - Journal of the American Medical Association, 2019, 322, 1137.	7.4	18
60	Potential Unintended Effects of Medicare's Bundled Payments for Care Improvement Program"Reply. JAMA - Journal of the American Medical Association, 2019, 321, 107.	7.4	2
61	Accelerated Approval of Cancer Drugs"Righting the Ship of the US Food and Drug Administration. JAMA Internal Medicine, 2019, 179, 922.	5.1	14
62	Artificial Intelligence in Health Care. JAMA - Journal of the American Medical Association, 2019, 321, 2281.	7.4	162
63	Next Phase in Effective Cost Control in Health Care. JAMA - Journal of the American Medical Association, 2019, 321, 1151.	7.4	12
64	When Is The Price Of A Drug Unjust? The Average Lifetime Earnings Standard. Health Affairs, 2019, 38, 604-612.	5.2	16
65	Effect of Financial Bonus Size, Loss Aversion, and Increased Social Pressure on Physician Pay-for-Performance. JAMA Network Open, 2019, 2, e187950.	5.9	17
66	Population-Based Primary Care Payment System in Hawaii"Reply. JAMA - Journal of the American Medical Association, 2019, 322, 2136.	7.4	1
67	Pricing a Year of Progression-Free Survival. JAMA Dermatology, 2019, 155, 15.	4.1	4
68	National Representativeness Of Hospitals And Markets In Medicare's Mandatory Bundled Payment Program. Health Affairs, 2019, 38, 44-53.	5.2	8
69	Characteristics of Hospitals Earning Savings in the First Year of Mandatory Bundled Payment for Hip and Knee Surgery. JAMA - Journal of the American Medical Association, 2018, 319, 930.	7.4	27
70	Measures of the Burden of Medical Expenses"Reply. JAMA - Journal of the American Medical Association, 2018, 319, 1621.	7.4	0
71	Does Medicine Overemphasize IQ?. JAMA - Journal of the American Medical Association, 2018, 319, 651.	7.4	40
72	The Real Cost of the US Health Care System. JAMA - Journal of the American Medical Association, 2018, 319, 983.	7.4	43

#	ARTICLE	IF	CITATIONS
73	Volume Increases and Shared Decision-making in Joint Replacement Bundles. <i>Annals of Surgery</i> , 2018, 267, 35-36.	4.2	4
74	Pitfalls and Potential in Medicare's Move Toward Outpatient Care Episodes. <i>Annals of Internal Medicine</i> , 2018, 169, 802.	3.9	3
75	Outcomes for individuals turned down for living kidney donation. <i>Clinical Transplantation</i> , 2018, 32, e13408.	1.6	21
76	Association of Hospital Participation in a Medicare Bundled Payment Program With Volume and Case Mix of Lower Extremity Joint Replacement Episodes. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 901.	7.4	53
77	Brain leaks and consumer neurotechnology. <i>Nature Biotechnology</i> , 2018, 36, 805-810.	17.5	104
78	Aligning Patient and Physician Incentives. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1635.	7.4	4
79	Comparison Of Hospitals Participating In Medicare's Voluntary And Mandatory Orthopedic Bundle Programs. <i>Health Affairs</i> , 2018, 37, 854-863.	5.2	27
80	Redesigning provider payment: Opportunities and challenges from the Hawaii experience. <i>Healthcare</i> , 2018, 6, 168-174.	1.3	5
81	The Status of End-of-Life Care in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 239.	7.4	16
82	Importance of Intelligence and Emotional Intelligence for Physicians's Reply. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 205.	7.4	0
83	Dilemmas in access to medicines: a humanitarian perspective " Authors' reply. <i>Lancet, The</i> , 2017, 389, 1008-1009.	13.7	3
84	Conflicts of Interest for Patient-Advocacy Organizations. <i>New England Journal of Medicine</i> , 2017, 376, 880-885.	27.0	125
85	Why There Are No "Potential" Conflicts of Interest. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1721.	7.4	58
86	The Next Generation of Episode-Based Payments. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2371.	7.4	15
87	Physicians, Not Conscripts " Conscientious Objection in Health Care. <i>New England Journal of Medicine</i> , 2017, 376, 1380-1385.	27.0	122
88	Priorities for Public Health Spending's Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1278.	7.4	1
89	Reassessing the Data on Whether a Physician Shortage Exists. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1945.	7.4	59
90	Cost of Joint Replacement Using Bundled Payment Models. <i>JAMA Internal Medicine</i> , 2017, 177, 214.	5.1	266

#	ARTICLE	IF	CITATIONS
91	Motivations, enrollment decisions, and socio-demographic characteristics of healthy volunteers in phase 1 research. <i>Clinical Trials</i> , 2017, 14, 526-536.	1.6	41
92	Shortage or Surplus of Physicians in the United Statesâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1070.	7.4	0
93	Measuring the Burden of Health Care Costs on US Families. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1863.	7.4	36
94	Phase 1 healthy volunteer willingness to participate and enrollment preferences. <i>Clinical Trials</i> , 2017, 14, 537-546.	1.6	25
95	Conscientious Objection in Health Care. <i>New England Journal of Medicine</i> , 2017, 377, 96-98.	27.0	4
96	A randomized trial comparing concise and standard consent forms in the START trial. <i>PLoS ONE</i> , 2017, 12, e0172607.	2.5	28
97	Attitudes and Practices of Euthanasia and Physician-Assisted Suicide in the United States, Canada, and Europe. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 79.	7.4	462
98	Characteristics of Patients Dying With Cancer in Developed Countriesâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2732.	7.4	0
99	How Can the United States Spend Its Health Care Dollars Better?. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2604.	7.4	8
100	The ethics of expanding access to cheaper, less effective treatments. <i>Lancet</i> , 2016, 388, 932-934.	13.7	22
101	Addressing conflicts of interest of public speakers at advisory committee meetings. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 267-268.	27.6	5
102	Addressing exploitation of poor clinical trial participants in North America and the European Union. <i>European Journal of Internal Medicine</i> , 2016, 34, e37-e38.	2.2	0
103	Predicting the Future â€” Big Data, Machine Learning, and Clinical Medicine. <i>New England Journal of Medicine</i> , 2016, 375, 1216-1219.	27.0	1,955
104	Six health care trends that will reshape the patient-provider dynamic. <i>Healthcare</i> , 2016, 4, 148-150.	1.3	7
105	The End of Radiology? Three Threats to the Future Practice of Radiology. <i>Journal of the American College of Radiology</i> , 2016, 13, 1415-1420.	1.8	115
106	Euthanasia and Physician-Assisted Suicideâ€”In Reply. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1600.	7.4	6
107	Physician Peer Comparisons as a Nonfinancial Strategy to Improve the Value of Care. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1759.	7.4	62
108	The potential exploitation of research participants in high income countries who lack access to health care. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 857-864.	2.4	19

#	ARTICLE	IF	CITATIONS
109	Comparison of Site of Death, Health Care Utilization, and Hospital Expenditures for Patients Dying With Cancer in 7 Developed Countries. JAMA - Journal of the American Medical Association, 2016, 315, 272.	7.4	388
110	A Call for Value in Cancer Research. JAMA Oncology, 2016, 2, 11.	7.1	16
111	How Well Is the Affordable Care Act Doing?. JAMA - Journal of the American Medical Association, 2016, 315, 1331.	7.4	7
112	Risks of phase I research with healthy participants: A systematic review. Clinical Trials, 2016, 13, 149-160.	1.6	43
113	Quantifying the risks of non-oncology phase I research in healthy volunteers: meta-analysis of phase I studies. BMJ, The, 2015, 350, h3271-h3271.	6.0	56
114	Reform of Clinical Research Regulations, Finally. New England Journal of Medicine, 2015, 373, 2296-2299.	27.0	27
115	Making Cuts to Medicare: The Views of Patients, Physicians, and the Public. Journal of Clinical Oncology, 2015, 33, 846-853.	1.6	5
116	Clinical research: Should patients pay to play?. Science Translational Medicine, 2015, 7, 298ps16.	12.4	22
117	Public health, universal health coverage, and Sustainable Development Goals: can they coexist?. Lancet, The, 2015, 386, 928-930.	13.7	115
118	Patient Demands and Requests for Cancer Tests and Treatments. JAMA Oncology, 2015, 1, 33.	7.1	34
119	Improving Long-term Psychiatric Care. JAMA - Journal of the American Medical Association, 2015, 313, 243.	7.4	90
120	Enhancing Professionalism Through Management. JAMA - Journal of the American Medical Association, 2015, 313, 1799.	7.4	12
121	Hypofractionated Whole Breast Irradiation for Early-Stage Breast Cancer—Reply. JAMA - Journal of the American Medical Association, 2015, 313, 1371.	7.4	2
122	Expanding Long-term Care Options for Persons With Serious Mental Illness—Reply. JAMA - Journal of the American Medical Association, 2015, 313, 1757.	7.4	0
123	Compassionate use of experimental drugs in the Ebola outbreak — Authors' reply. Lancet, The, 2014, 384, 1844.	13.7	4
124	Ethical considerations of experimental interventions in the Ebola outbreak. Lancet, The, 2014, 384, 1896-1899.	13.7	110
125	NCDs and an outcome-based approach to global health. Lancet, The, 2014, 384, 2003-2004.	13.7	6
126	Why Should High-Income Countries Help Combat Ebola?. JAMA - Journal of the American Medical Association, 2014, 312, 1297.	7.4	30

#	ARTICLE	IF	CITATIONS
127	Declaration of Helsinki and Protection for Vulnerable Research Participants”Reply. JAMA - Journal of the American Medical Association, 2014, 311, 1252.	7.4	4
128	Lowering Medical Costs Through the Sharing of Savings by Physicians and Patients. JAMA Internal Medicine, 2014, 174, 2009.	5.1	16
129	Controlling Costs by Expanding the Medicare Acute Care Episode Demonstration. JAMA Internal Medicine, 2014, 174, 1438.	5.1	19
130	Uptake and Costs of Hypofractionated vs Conventional Whole Breast Irradiation After Breast Conserving Surgery in the United States, 2008”2013. JAMA - Journal of the American Medical Association, 2014, 312, 2542.	7.4	184
131	Getting the Next Version of Payment Policy “Right”on the Road Toward Accountable Cancer Care. International Journal of Radiation Oncology Biology Physics, 2014, 89, 954-957.	0.8	11
132	Patient demand for care: How much does this contribute to inappropriate tests and treatments?. Journal of Clinical Oncology, 2014, 32, 6530-6530.	1.6	1
133	Reconsidering the Declaration of Helsinki. Lancet, The, 2013, 381, 1532-1533.	13.7	59
134	Going to the Moon in Health Care. JAMA - Journal of the American Medical Association, 2013, 310, 1925.	7.4	3
135	The Future of Biomedical Research. JAMA - Journal of the American Medical Association, 2013, 309, 1589.	7.4	26
136	Health Care Cost Control and Views of Physicians”Reply. JAMA - Journal of the American Medical Association, 2013, 310, 2201.	7.4	0
137	Impact of oncology drug shortages.. Journal of Clinical Oncology, 2013, 31, CRA6510-CRA6510.	1.6	1
138	Impact of oncology drug shortages.. Journal of Clinical Oncology, 2013, 31, CRA6510-CRA6510.	1.6	1
139	Patient, public, and oncologists”™ attitudes toward rationing medical care.. Journal of Clinical Oncology, 2013, 31, 6518-6518.	1.6	0
140	Physician Autonomy and Health Care Reform. JAMA - Journal of the American Medical Association, 2012, 307, 367-8.	7.4	59
141	Shortening Medical Training by 30%. JAMA - Journal of the American Medical Association, 2012, 307, 1143.	7.4	126
142	Why Accountable Care Organizations Are Not 1990s Managed Care Redux. JAMA - Journal of the American Medical Association, 2012, 307, 2263-4.	7.4	26